research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
Search
for
Sort by
Research
540-570 / 1000+ resultsresearch Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
Adalimumab helped control a child's severe eye disease when other treatments failed.
research Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin
Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
research Hair loss with levetiracetam in five patients with epilepsy
Levetiracetam may cause hair loss, which can potentially reverse with lower doses or stopping the drug.
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research Alopecia associated with ritonavir-boosted atazanavir therapy
A man's hair loss was linked to his HIV medication, which improved after changing drugs.
research Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
research Tofacitinib in a Recalcitrant Case of Alopecia Areata
Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Polydeoxyribonucleotide as a Regenerative Agent in Dermatology and Wound Healing: Mechanisms, Clinical Applications, and Safety
PDRN is effective and safe for healing wounds and skin issues.
research Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia
Vinblastine can help treat childhood ITP but may cause reversible side effects.
research Apremilast is efficacious in refractory alopecia areata
Apremilast helps regrow hair in hard-to-treat alopecia areata.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research Transcriptome-guided development of a fibrosis-reversal compound reduces skin scarring and allows regeneration via mitochondrial uncoupling
The study investigates the efficacy of a compound, FR-1, in reducing skin scarring and promoting regeneration through mitochondrial uncoupling. Tested on scar-derived fibroblasts from 6 patients and in a murine wound model, FR-1 significantly reduced scar size and preserved hair follicles without adverse effects like skin atrophy or hair follicle damage, unlike current therapies such as triamcinolone acetonide (TA). FR-1 works by inhibiting fibroblast proliferation and remodeling the extracellular matrix, showing potential for broader applications in fibrosis treatment. The compound demonstrated enhanced stability and solubility, with minimal systemic absorption and no adverse effects on major organs, suggesting its potential as a therapeutic agent for scarless healing.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research 577 Successful allogeneic epidermal grafting of chronic recessive dystrophic epidermolysis bullosa wounds from hematopoietic cell donors in the outpatient setting
Skin grafts from related donors significantly healed chronic wounds in patients with a severe skin condition over a year.
research A single center, pilot, double-blinded, randomized, comparative, prospective clinical study to evaluate improvements in the structure and function of facial skin with tazarotene 0.1% cream alone and in combination with GliSODin® Skin Nutrients Advanced A
Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Systemic tofacitinib in paediatric alopecia areata
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Efficacy and safety of oral alitretinoin in chronic hand eczema and palmoplantar pustulosis
Oral alitretinoin is effective for certain types of chronic hand eczema, with mild side effects.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Safety and Effectiveness of VYC-15L, a Hyaluronic Acid Filler for Lip and Perioral Enhancement: One-Year Results From a Randomized, Controlled Study
VYC-15L is a safe and effective lip filler that lasts up to a year.
research The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
Apremilast may help treat hair loss in alopecia areata.
research Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
Valproic Acid could potentially be used to treat immune-related conditions due to its ability to modify immune cell functions.